• The technology described in this briefing is Acumen IQ sensor with Acumen hypotension prediction index (HPI) software. It uses a machine-learning algorithm to predict the risk of a hypotensive event and provides information to help identify the cause.

  • The innovative aspects are that the technology is claimed to predict hypotension up to 15 minutes before an event.

  • The intended place in therapy would be to predict the chance of a hypotensive event happening during surgical and non-surgical cases in which an arterial line for blood pressure monitoring is recommended.

  • The main points from the evidence summarised in this briefing are from 6 studies (including 3 randomised controlled trials) of 878 adults in intensive care or needing high-risk surgery. They show that Acumen IQ with Acumen HPI software is effective in predicting hypotensive events.

  • Key uncertainties around the evidence or technology are that there is limited evidence for people in intensive care and limited evidence on patient outcomes.

  • The cost of Acumen IQ sensor is £400 per unit (excluding VAT) and the HemoSphere monitor costs £27,470 (excluding VAT). There is currently no evidence to suggest that this technology is cost saving.